ArticleCell host & microbe2020
Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies.
Open access · greenAbstract read
In one paragraph
Article in Cell host & microbe, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia.Vaccine · 2022Trial
- Dengue virus envelope epitope-specific antibodies are associated with protection from severe dengue.EMBO molecular medicine · 2026Article
- Ultrapotent human antibodies lock E protein dimers central region of diverse DENV3 morphological variants.Nature communications · 2025Article
- Targeted Lymph Node Immunization with Serotype-Specific Dengue VLP Vaccines Enhances Antibody Avidity and Specificity.Vaccines · 2025Article
- Protective envelope dimer epitope-like antibodies are elicited against dengue virus in children after infection and vaccination.Science translational medicine · 2025Article
- Multivalent administration of dengue E dimers on liposomes elicits type-specific neutralizing responses without immune interference.NPJ vaccines · 2025Article
- Article
- Stabilized dengue virus 2 envelope subunit vaccine redirects the neutralizing antibody response to all E-domains.Journal of virology · 2025Article
- A single residue in domain II of envelope protein of yellow fever virus is critical for neutralization sensitivity.Journal of virology · 2025Article
- Animal Models, Therapeutics, and Vaccine Approaches to Emerging and Re-Emerging Flaviviruses.Viruses · 2024Review
- Dengue Virus Serotype 3 Origins and Genetic Dynamics, Jamaica.Emerging infectious diseases · 2024Article
- Article
- Preclinical Evaluation of Novel Sterically Optimized VLP-Based Vaccines against All Four DENV Serotypes.Vaccines · 2024Article
- Homotypic antibodies target novel E glycoprotein domains after natural DENV 3 infection/vaccination.Cell host & microbe · 2023Article
- Article
- Article
- Evolution of a Functionally Intact but Antigenically Distinct DENV Fusion Loop.bioRxiv : the preprint server for biology · 2023Article
- Evolutionary dynamics of dengue virus in India.PLoS pathogens · 2023Article
- A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity.Nature communications · 2023Article
- Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement.Frontiers in immunology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
27 authors at 5 institutions in 2 countries.
Ellen YoungDepartment of Epidemiology, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA.
Robert H CarnahanDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Daniela V AndradeDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California Berkeley, Berkeley, CA, USA.
Nurgun KoseVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Rachel S NargiVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Ethan J FritchDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Jennifer E MuntDepartment of Epidemiology, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA.
Michael P DoyleVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Laura WhiteDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Thomas J BaricDepartment of Epidemiology, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA.
Mark StoopsDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Aravinda DeSilvaDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Longping V TseDepartment of Epidemiology, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA.
David R MartinezDepartment of Epidemiology, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA.
Deanna ZhuDepartment of Epidemiology, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA.
Stefan MetzDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Marcus P WongDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California Berkeley, Berkeley, CA, USA.
Diego A EspinosaDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California Berkeley, Berkeley, CA, USA.
Magelda MontoyaDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California Berkeley, Berkeley, CA, USA.
Scott B BieringDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California Berkeley, Berkeley, CA, USA.
Soila Sukulpolvi-PettyDepartment of Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA.
Guillermina KuanHealth Center Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua.
Angel BalmasedaNational Virology Laboratory, National Center for Diagnosis and Reference, Ministry of Health, Managua, Nicaragua.
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA; Molecular Microbiology, Washington University School of Medicine, Saint Louis, MO 63110, USA; Pathology & Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California Berkeley, Berkeley, CA, USA. Electronic address: eharris@berkeley.edu.
James E CroweDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: james.crowe@vumc.org.
Ralph S BaricDepartment of Epidemiology, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA; Department of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA. Electronic address: rbaric@email.unc.edu.
University of North Carolina at Chapel Hill · USUniversity of California, Berkeley · USVanderbilt University Medical Center · USWashington University in St. Louis · USMinistry of Health · RW
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8MVANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MT Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Daniela Weiskopf · 2015 to 2026
$34.1MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9MAntibody-based Protection against FlavivirsesR01AI073755 · NIAID · WASHINGTON UNIVERSITY · PI DIAMOND, MICHAEL S, FREMONT, DAVED H. · 2007 to 2022
$11.4MINFECTIOUS DISEASE PATHOGENESIS TRAININGT32AI007151 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, JONATHAN J · 1985 to 2024
$5.5MMolecular Basis of Flavivirus Cross-Neutralization by Human AntibodiesR01AI107731 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESILVA, ARAVINDA M. · 2013 to 2022
$5.3MEpidemiological, Clinical & Immunological Studies of Zika, dengue and chikungunyaR01AI099631 · NIAID · SUSTAINABLE SCIENCES INSTITUTE · PI BALMASEDA, ANGEL LAZARO · 2012 to 2021
$1.8MAge in dengue antibody response and risk after primary natural infectionF30AI160898 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ZHU, DEANNA · 2021 to 2024
$170kCharacterizing the human antibody response to henipavirus infectionF31AI152332 · NIAID · VANDERBILT UNIVERSITY · PI DOYLE, MICHAEL P · 2020 to 2021
$40kNCATS NIH HHS UL1 TR000445NCI NIH HHS P30 CA068485NCRR NIH HHS UL1 RR024975NIAID NIH HHS F30 AI160898NIAID NIH HHS F31 AI152332NIAID NIH HHS P01 AI106695NIAID NIH HHS R01 AI073755NIAID NIH HHS R01 AI099631NIAID NIH HHS R01 AI107731NIAID NIH HHS T32 AI007151NIDDK NIH HHS P30 DK058404
Abstract
The rational design of dengue virus (DENV) vaccines requires a detailed understanding of the molecular basis for antibody-mediated immunity. The durably protective antibody response to DENV after primary infection is serotype specific. However, there is an incomplete understanding of the antigenic determinants for DENV type-specific (TS) antibodies, especially for DENV serotype 3, which has only one well-studied, strongly neutralizing human monoclonal antibody (mAb). Here, we investigated the human B cell response in children after natural DENV infection in the endemic area of Nicaragua and isolated 15 DENV3 TS mAbs recognizing the envelope (E) glycoprotein. Functional epitope mapping of these mAbs and small animal prophylaxis studies revealed a complex landscape with protective epitopes clustering in at least 6-7 antigenic sites. Potently neutralizing TS mAbs recognized sites principally in E glycoprotein domains I and II, and patterns suggest frequent recognition of quaternary structures on the surface of viral particles.
Indexed as
SerogroupAdolescentAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralB-LymphocytesChildChild, PreschoolChlorocebus aethiopsDengueDengue VaccinesDengue VirusEpitope MappingEpitopesHumansAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralDengue VaccinesEpitopesViral Envelope Proteinsantigenic sitechimeric virusdengue virus serotype 3DENV3envelope proteinflavivirusfunctional epitopesin vivo protectionneutralizing monoclonal antibodies
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.